blurry thing 1

Developing the future of cancer screening.

We believe the future of preventive care starts with empowering individual health ownership.

GettyImages 1221576332 blue

Disruptive Science.

Innovative Solutions.

Proactive Health.

Our Team

omid m

Omid Moghadam

Founder & CEO

ChrisHeadshot

Chris Albertson, MD

Laboratory Medical Director

IMG 0348 c2 Namida

Eric Barnes

Chief Financial Officer

NamidaLab2021 7E7A3453

Kelsey Earhart

Technical Supervisor

NamidaLab2021 7E7A3403

Prashanth Ravishankar, Ph.D.

Research & Development Scientist

Amber headshot 2

Amber Alsbury

Manager of Customer Service

Our Advisors

Steve Harms

Steven Harms, MD, FACR, Emeritus

Clinical Advisory Board - Radiology

Klimberg Suzanne

Suzanne Klimberg, MD, MSHCT, PhD, FACS

Clinical Advisory Board - Breast Oncology

SimmonsHeadshots 3

Michael Clark

Advisory Board - Marketing & Ecommerce

TeresaFarahSQ

Teresa Farah

Advisory Board - Legal & Commercial Strategy

JamesFarleySQ

James Farley

Advisory Board - Managed Care & Insurance Markets

Halsey HeadshotSQ

John Halsey

Advisory Board - Managed Care & Employer Markets

KeithOrrisSQ v2

Keith A. Orris

Advisory Board - Corporate Strategy & Business Development

Marcus Photo Proof 2022.JPG

Marcus Osborne

Advisory Board - Healthcare Delivery & Strategy

Ed

Ed Fryar

Board of Directors

Rob+Kimbel+headshot+2020

Rob Kimbel

Board of Directors

Todd+Simmons+Closeup+2016

Todd Simmons

Board of Directors

Ran1

Ran Whitehead

Board of Directors

Why Namida?

Harnessing the Healing Power of Tears in the Fight Against Cancer

Our name, Namida, is derived from the Japanese word for tears, reflecting our focus on utilizing the power of tears to identify early-stage cancers. We use cutting-edge proteomics and genomics technologies to analyze the unique biomarkers present in tears, which can indicate the presence of cancer.

GettyImages 1410329966 blue

Let’s disrupt.

We’re a revenue stage biotech company with big ideas, and the science to make them happen.

Be a part of the future of cancer screening.